We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
14 own
21 watching
Current Price
$0
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
42.58M
52-Week High
5.36
52-Week Low
1.05
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization42.58M
52-Week High5.36
52-Week Low1.05
Average Volume0.01M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Atreca Inc is a biopharmaceutical company utilizing a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Their approach relies on the human immune system to direct them to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. They believe the fact that their approach has the potential to deliver novel, previously unexplored immuno-oncology targets provides them with a significant competitive advantage over traditional approaches which focus on known targets that many companies are aware of and can pursue. They have utilized their drug discovery approach to identify over 1,400 distinct human antibodies that bind preferentially to tumor tissue from patients who are not the source of the antibody. Their lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using their discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. They anticipate filing an Investigational New Drug, or IND, application for ATRC-101 in late 2019 and initiating a Phase 1b clinical trial in patients with solid tumors in early 2020, subject to U.S. Food and Drug Administration, or FDA, approval of their IND application. They were incorporated under the laws of the state of Delaware in 2010 under the name Atreca, Inc. Their principal executive offices are located at 500 Saginaw Drive, Redwood City, CA 94063.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
2 months ago
Atreca, Inc. (NASDAQ:BCEL Get Rating) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 2,730,000 shares, a drop of 7.8% from the July 31st total of 2,960,000 shares. Approximately 9.7% of the shares of the company are short sold. Based...
Zolmax
6 months ago
Atreca (NASDAQ:BCEL Get Rating) had its price objective dropped by research analysts at Robert W. Baird from $12.00 to $9.00 in a research note issued on Thursday, The Fly reports. Robert W. Bairds price objective suggests a potential upside of 389.13% from the stocks previous close. A number of ...
Ticker Report
7 months ago
Equities research analysts expect Atreca, Inc. (NASDAQ:BCEL Get Rating) to report earnings of ($0.78) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atrecas earnings, with estimates ranging from ($0.82) to ($0.72). Atreca ...
Zolmax
7 months ago
Brokerages predict that Atreca, Inc. (NASDAQ:BCEL Get Rating) will report earnings of ($0.78) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Atrecas earnings. The lowest EPS estimate is ($0.82) and the highest is ($0.72). Atreca reported ...
PR Newswire
8 months ago
Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca? Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca? PR Newswire NEW YORK, March 9, 2022 NEW YORK, March...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00